Spectrum Of Activity
HIV infection 25 mg PO q24h
If co-administrated with Rifabutin, 50 mg PO q24h
Safety and efficacy in pediatric patients have not been established
Mild or moderate hepatic impairment No dose adjustment
Severe hepatic impairment No data
Mild or moderate renal adjustment No dose adjustment
Severe renal impairment, ESRD Use with caution
Treatment of HIV infection.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin at baseline and with modification of treatment.
Increased liver enzymes
Mesangial proliferative glomerulonephritis
Proton pump inhibitors
QT prolonging drugs
St. John’s Wort
Antimicrobial class: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: B
Average serum half life: 50 hours
Precautions: QT interval prolongation has been reported; use with caution with coadministration of other medications associated with an increased risk of torsade de pointes.
Monitoring recommended with underlying hepatic disease or marked elevations in baseline transaminases; consider monitoring in patients without preexisting hepatic impairment or other risk factors.
Discontinue immediately if signs or symptoms of severe skin and hypersensitivity reactions develop.
Depressive disorders have been reported; evaluate benefit and risk of continued treatment.